{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:44Z","timestamp":1781646704887,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary cytoreductive surgery is a feasible treatment option in recurrent ovarian cancer. Patient selection for surgery remains challenging, as conventional imaging, such as CT and MRI, is unreliable for predicting complete gross resection. PET\/CT is a modality that combines metabolic and anatomical imaging. Although there are studies supporting the use of PET\/CT in ovarian cancer, there is very limited evidence specifically assessing PET\/CT-guided selection for secondary cytoreductive surgery under the latest eligibility criteria. This study aims to evaluate the added value of PET\/CT for predicting no residual tumor volume after secondary surgical cytoreduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective data collection on patients diagnosed with ovarian cancer who underwent a PET\/CT examination between 2018 and 2023 in our center. Patients with suspected recurrence considered for secondary cytoreduction based on conventional imaging and clinical criteria, were included in our analysis. Besides descriptive statistics we performed decision curve analysis (DCA) to determine the added value of PET\/CT in surgical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>22 patients were potentially eligible for secondary debulking according to clinical criteria and conventional imaging findings. 13\/22 patients were found to be operable based on preoperative PET\/CT results, and 11\/13 had a successful resection (no gross residual tumor) (PPV: 85%). 9\/22 patients were found ineligible for secondary cytoreduction based on PET\/CT results. 7\/9 had inoperable lesions, and in two cases, no malignant lesions were detected. Decision curve analysis showed that PET\/CT provided superior clinical utility compared to both conventional imaging and a \u201ctreat none\u201d approach, yielding a higher net benefit across a broad range of surgical decision thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrate that PET\/CT adds significant clinical value in selecting appropriate candidates for secondary cytoreduction, mainly by reinforcing potential operability. These findings suggest that PET\/CT may provide incremental information during preoperative assessment; however, prospective validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15898-3","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:15:06Z","timestamp":1774498506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of PET\/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Csaba","family":"Csikos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antal","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Hascsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"B\u00e1tyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Garai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e1rd Tibor","family":"Krasznai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"3","key":"15898_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"15898_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","volume":"32","author":"KM Elias","year":"2018","unstructured":"Elias KM, Guo J, Bast RC Jr. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903\u201314. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.003.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"15898_CR3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.21037\/gs-20-325","volume":"9","author":"S Garzon","year":"2020","unstructured":"Garzon S, Lagan\u00e0 AS, Casarin J, Raffaelli R, Cromi A, Franchi M, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118\u201329. https:\/\/doi.org\/10.21037\/gs-20-325.","journal-title":"Gland Surg"},{"issue":"1(Suppl 1)","key":"15898_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(1(Suppl 1)):61\u201385. https:\/\/doi.org\/10.1002\/ijgo.13878.","journal-title":"Int J Gynaecol Obstet"},{"issue":"10","key":"15898_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.011.","journal-title":"Ann Oncol"},{"issue":"23","key":"15898_CR6","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2103294.","journal-title":"N Engl J Med"},{"issue":"4","key":"15898_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(21)00006-1.","journal-title":"Lancet Oncol"},{"issue":"14","key":"15898_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142613","volume":"16","author":"AS Myhr","year":"2024","unstructured":"Myhr AS, Bj\u00f8rge L, Torkildsen CF. Secondary cytoreductive surgery in relapsed platinum-sensitive epithelial ovarian cancer: a systematic review of randomized controlled trials. Cancers (Basel). 2024;16(14):2613. https:\/\/doi.org\/10.3390\/cancers16142613.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"15898_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1902626.","journal-title":"N Engl J Med"},{"issue":"3","key":"15898_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35(3):248\u201366. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.015.","journal-title":"Ann Oncol"},{"issue":"12","key":"15898_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702\u201310. https:\/\/doi.org\/10.1245\/s10434-006-9058-0.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"15898_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. a project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289\u201395. https:\/\/doi.org\/10.1097\/IGC.0b013e31820aaafd.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"15898_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040646","volume":"17","author":"M Duchon","year":"2025","unstructured":"Duchon M, Naik R, Lecuru F, Ferron G, Cornou C, Madad Zadeh S, et al. Management of recurrence in ovarian cancer-the role of surgery and HIPEC with relevance to BRCA testing in a PARPi landscape. Cancers (Basel). 2025;17(4):646. https:\/\/doi.org\/10.3390\/cancers17040646.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"15898_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11912-023-01480-8","volume":"26","author":"C Fotopoulou","year":"2024","unstructured":"Fotopoulou C, Eriksson AG, Yagel I, Chang SJ, Lim MC. Surgery for recurrent epithelial ovarian cancer. Curr Oncol Rep. 2024;26(1):46\u201354. https:\/\/doi.org\/10.1007\/s11912-023-01480-8.","journal-title":"Curr Oncol Rep"},{"key":"15898_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.674637","volume":"11","author":"C Jiang","year":"2021","unstructured":"Jiang C, Li Z. Prediction models for complete resection in secondary cytoreductive surgery of patients with recurrent ovarian cancer. Front Oncol. 2021;11:674637. https:\/\/doi.org\/10.3389\/fonc.2021.674637.","journal-title":"Front Oncol"},{"issue":"3","key":"15898_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ygyno.2018.03.001","volume":"149","author":"JO Schorge","year":"2018","unstructured":"Schorge JO, Bregar AJ, Durfee J, Berkowitz RS. Meigs to modern times: the evolution of debulking surgery in advanced ovarian cancer. Gynecol Oncol. 2018;149(3):447\u201354. https:\/\/doi.org\/10.1016\/j.ygyno.2018.03.001.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"15898_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","volume":"125","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u201coptimal\u201d residual disease. Gynecol Oncol. 2012;125(2):483\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.024.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"15898_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","volume":"21","author":"KK Shih","year":"2010","unstructured":"Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010;21(2):75\u201380. https:\/\/doi.org\/10.3802\/jgo.2010.21.2.75.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"15898_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00261-018-1677-y","volume":"44","author":"L Manganaro","year":"2019","unstructured":"Manganaro L, Gigli S, Antonelli A, Saldari M, Tomao F, Marchetti C, et al. Imaging strategy in recurrent ovarian cancer: a practical review. Abdom Radiol (NY). 2019;44(3):1091\u2013102. https:\/\/doi.org\/10.1007\/s00261-018-1677-y.","journal-title":"Abdom Radiol (NY)"},{"issue":"10","key":"15898_CR20","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1007\/s00259-021-05450-9","volume":"48","author":"RC Delgado Bolton","year":"2021","unstructured":"Delgado Bolton RC, Aide N, Colletti PM, Ferrero A, Paez D, Skanjeti A, et al. EANM guideline on the role of 2-[18F]FDG PET\/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging. 2021;48(10):3286\u2013302. https:\/\/doi.org\/10.1007\/s00259-021-05450-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"15898_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MNM.0000000000000477","volume":"37","author":"A Tawakol","year":"2016","unstructured":"Tawakol A, Abdelhafez YG, Osama A, Hamada E, El Refaei S. Diagnostic performance of 18F-FDG PET\/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy. Nucl Med Commun. 2016;37(5):453\u201360. https:\/\/doi.org\/10.1097\/MNM.0000000000000477.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"15898_CR22","doi-asserted-by":"publisher","first-page":"W464","DOI":"10.2214\/AJR.09.3843","volume":"194","author":"P Prakash","year":"2010","unstructured":"Prakash P, Cronin CG, Blake MA. Role of PET\/CT in ovarian cancer. AJR Am J Roentgenol. 2010;194(6):W464\u201370. https:\/\/doi.org\/10.2214\/AJR.09.3843.","journal-title":"AJR Am J Roentgenol"},{"issue":"16","key":"15898_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161740","volume":"14","author":"C Csikos","year":"2024","unstructured":"Csikos C, Czina P, Moln\u00e1r S, Kov\u00e1cs AR, Garai I, Krasznai ZT. Predicting complete cytoreduction with preoperative [18F]FDG PET\/CT in patients with ovarian cancer: a systematic review and meta-analysis. Diagnostics. 2024;14(16):1740. https:\/\/doi.org\/10.3390\/diagnostics14161740.","journal-title":"Diagnostics"},{"issue":"4","key":"15898_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/IGC.0b013e3181a3cc94","volume":"19","author":"S Risum","year":"2009","unstructured":"Risum S, H\u00f8gdall C, Markova E, Berthelsen AK, Loft A, Jensen F, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009;19(4):600\u20134. https:\/\/doi.org\/10.1111\/IGC.0b013e3181a3cc94.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"15898_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.suronc.2017.07.004","volume":"26","author":"A Amit","year":"2017","unstructured":"Amit A, Hodes A, Lavie O, Keidar Z, Matanes E, Lowenstein L. The role of F18-FDG PET\/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer. Surg Oncol. 2017;26(4):347\u201351. https:\/\/doi.org\/10.1016\/j.suronc.2017.07.004.","journal-title":"Surg Oncol"},{"issue":"3","key":"15898_CR26","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e36","volume":"29","author":"YJ Lee","year":"2018","unstructured":"Lee YJ, Kim YM, Jung PS, Lee JJ, Kim JK, Kim YT, et al. Diagnostic value of integrated 1\u2078F-fluoro-2-deoxyglucose positron emission tomography\/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients. J Gynecol Oncol. 2018;29(3):e36. https:\/\/doi.org\/10.3802\/jgo.2018.29.e36.","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"15898_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565\u201374. https:\/\/doi.org\/10.1177\/0272989X06295361.","journal-title":"Med Decis Making"},{"issue":"12","key":"15898_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123000","volume":"14","author":"AE Salem","year":"2022","unstructured":"Salem AE, Fine GC, Covington MF, Koppula BR, Wiggins RH, Hoffman JM, et al. PET-CT in clinical adult oncology-IV. Gynecologic and genitourinary malignancies. Cancers (Basel). 2022;14(12):3000. https:\/\/doi.org\/10.3390\/cancers14123000.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"15898_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092407","volume":"15","author":"EKA Triumbari","year":"2023","unstructured":"Triumbari EKA, Rufini V, Mingels C, Rominger A, Alavi A, Fanfani F, et al. Long axial field-of-view PET\/CT could answer unmet needs in gynecological cancers. Cancers (Basel). 2023;15(9):2407. https:\/\/doi.org\/10.3390\/cancers15092407.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"15898_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040717","volume":"16","author":"EP Olthof","year":"2024","unstructured":"Olthof EP, Wenzel HHB, van der Velden J, Stalpers LJA, Mom CH, van der Aa MA. Treatment strategies guided by [18F]FDG-PET\/CT in patients with locally advanced cervical cancer and [18F]FDG-positive lymph nodes. Cancers (Basel). 2024;16(4):717. https:\/\/doi.org\/10.3390\/cancers16040717.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"15898_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/IGC.0000000000000074","volume":"24","author":"Y Tanizaki","year":"2014","unstructured":"Tanizaki Y, Kobayashi A, Shiro M, Ota N, Takano R, Mabuchi Y, et al. Diagnostic value of preoperative SUVmax on FDG-PET\/CT for the detection of ovarian cancer. Int J Gynecol Cancer. 2014;24(3):454\u201360. https:\/\/doi.org\/10.1097\/IGC.0000000000000074.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"15898_CR32","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/IGC.0b013e3181e82a7f","volume":"20","author":"P Bhosale","year":"2010","unstructured":"Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, et al. Clinical utility of positron emission tomography\/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010;20(6):936\u201344. https:\/\/doi.org\/10.1111\/IGC.0b013e3181e82a7f.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"15898_CR33","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1007\/s00330-015-3729-9","volume":"25","author":"HA Vargas","year":"2015","unstructured":"Vargas HA, Burger IA, Goldman DA, Micc\u00f2 M, Sosa RE, Weber W, et al. Volume-based quantitative FDG PET\/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol. 2015;25(11):3348\u201353. https:\/\/doi.org\/10.1007\/s00330-015-3729-9.","journal-title":"Eur Radiol"},{"issue":"2","key":"15898_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejogrb.2008.05.006","volume":"140","author":"SM Lenhard","year":"2008","unstructured":"Lenhard SM, Burges A, Johnson TR, Kirschenhofer A, Bruns C, Linke R, et al. Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):263\u20138. https:\/\/doi.org\/10.1016\/j.ejogrb.2008.05.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"15898_CR35","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e31","volume":"34","author":"RL Nunes","year":"2023","unstructured":"Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, et al. The value of PET\/CT for cytoreductive surgery selection in recurrent ovarian carcinoma. J Gynecol Oncol. 2023;34(3):e31. https:\/\/doi.org\/10.3802\/jgo.2023.34.e31.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"15898_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00662-3","volume":"13","author":"TT Tsoi","year":"2020","unstructured":"Tsoi TT, Chiu KWH, Chu MY, Ngan HYS, Lee EYP. Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers. J Ovarian Res. 2020;13(1):61. https:\/\/doi.org\/10.1186\/s13048-020-00662-3.","journal-title":"J Ovarian Res"},{"issue":"11","key":"15898_CR37","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/aogs.14442","volume":"101","author":"J Wang","year":"2022","unstructured":"Wang J, Liu L, Pang H, Liu L, Jing X, Li Y. Preoperative PET\/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers. Acta Obstet Gynecol Scand. 2022;101(11):1315\u201327. https:\/\/doi.org\/10.1111\/aogs.14442.","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15898-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15898-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15898-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:19Z","timestamp":1781643199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15898-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15898"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15898-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the University of Debrecen (permission number: DE RKEB\/IKEB:5513\u20132020; date of approval: 15 June 2020). Consent to participate was waived by the Institutional Ethics Committee of the University of Debrecen due to retrospective data collection and anonymized data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ildik\u00f3 Garai, Zsolt Hascsi, and Ferenc B\u00e1tyi are employees of Scanomed Ltd. The paper reflects the views of the scientists, and not the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"572"}}